Search results
Bristol Myers' Revlimid Takes A 32% Hit As Generics Keep Coming
Investor's Business Daily· 1 year agoBristol Myers Squibb's Revlimid took fewer than expected generic hits in the fourth quarter,...
Bristol-Myers (BMY) Q4 Earnings Top, Revlimid Generic Impact Sales
Zacks via Yahoo Finance· 1 year agoBristol-Myers' (BMY) fourth-quarter 2022 earnings beat estimates, while sales declined year over...
Revlimid Generic Competition, Forex Impacts Bristol Myers' Q3 Sales; Reaffirms FY22 Guidance
Benzinga via Yahoo Finance· 2 years agoBristol Myers Squibb & Co (NYSE: BMY) said that its Q3 sales of $11.22 billion fell 3% Y/Y as...
Revlimid Generic Competition Hurts Bristol Myers' Q4 Earnings, Issues Annual Outlook Within Expected...
Benzinga via Yahoo Finance· 1 year agoBristol Myers Squibb & Co (NYSE: BMY) said that its Q4 sales of $11.41 billion fell 5% Y/Y as...
Bristol-Myers (BMY) Q2 Earnings, Sales Miss, '23 View Lowered
Zacks via Yahoo Finance· 10 months agoBristol-Myers' (BMY) second-quarter 2023 earnings and sales miss estimates due to generic erosion...
The Generics Are Here: How Bristol Myers Squibb Expects Patent Losses To Hit In 2022
Investor's Business Daily· 2 years agoBristol Myers Squibb reaffirmed expectations for a $10 billion pitfall from its generics-facing...
3 Generic Drug Stocks to Watch Amid Challenging Market Prospects
Zacks via Yahoo Finance· 2 months agoThe impact of macroeconomic headwinds on the Zacks Medical - Generic Drugs industry is gradually...
Bristol Myers' profit beats on better-than-feared Revlimid sales
Reuters via Yahoo Finance· 1 year ago(Reuters) -Bristol Myers Squibb Co on Thursday reported quarterly earnings that beat analysts'...
Bristol Myers sales fall, cuts 2023 forecast as drugs face competition
Reuters via Yahoo Finance· 10 months ago(Reuters) -Bristol Myers Squibb on Thursday said its second-quarter sales fell more than expected...
Will New Drugs Help Bristol Myers (BMY) Combat Generic Pressure?
Zacks via Yahoo Finance· 2 years agoBiotech bigwig Bristol Myers BMY has had a decent run this year despite one of its top drugs...